激素初治骨转移前列腺癌ADT治疗1年内血红蛋白浓度变化的临床与预后意义
本研究基于SCPG随机试验(编号5)中597例激素初治M1b前列腺癌患者,分析ADT治疗1年内血红蛋白(Hb)浓度变化对总生存的预测价值。多因素Cox分析显示,基线至3个月Hb下降者生存更好(HR 1.42,95%CI 1.11-1.80),6至12个月Hb下降者生存更差(HR 0.76,95%CI 0.62-0.92)。提示ADT期间Hb变化模式具有预后价值。
要点
- 基线至3个月Hb下降与更好生存相关(HR 1.42,95%CI 1.11-1.80)。
- 6至12个月Hb下降与更差生存相关(HR 0.76,95%CI 0.62-0.92)。
- 临床应关注ADT期间Hb变化模式的预后意义。
核心结论
- 在激素初治M1b前列腺癌患者中,ADT治疗基线至3个月Hb升高与显著更差生存相关,而6至12个月Hb升高与更好生存相关。
研究设计与样本
- 研究取自斯堪的纳维亚前列腺癌组(SPCG)编号5的随机试验,比较胃肠外雌激素与全雄激素阻断(TAB)在激素初治M1b前列腺癌中的疗效。
- 纳入597例在入组时及ADT治疗3、6、12个月时进行Hb测量的男性。
- 采用多因素Cox比例风险分析评估Hb浓度变化对总生存(OS)的时间依赖性影响,并用Kaplan-Meier曲线展示三个治疗期间Hb升高/降低对应的10年OS。
主要发现
- 多因素分析显示,基线至3个月Hb下降者较升高者生存更好(HR 1.42,95%CI 1.11-1.80)。
- 3至6个月Hb变化与生存无差异(HR 0.93,95%CI 0.76-1.12)。
- 6至12个月Hb下降者较升高者生存更差(HR 0.76,95%CI 0.62-0.92)。
临床怎么用
- 临床医生应知晓ADT治疗M1b前列腺癌期间Hb浓度变化具有预后价值。
- 需关注ADT不同时间段的Hb变化模式,而非仅看单时间点Hb水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the strength of change in haemoglobin (Hb) concentrations during 1 year of androgen-deprivation therapy (ADT) as a predictor of survival in hormone-naïve patients with bone-metastatic (Stage M1b) prostate cancer. PATIENTS AND METHODS: The patients included in this study were taken from the randomised trial (number 5) carried out by the Scandinavian Prostate Cancer Group (SPCG), comparing parenteral oestrogen with total androgen blockade (TAB) in hormone-naïve M1b prostate cancer. We identified 597 men where Hb measurements were made at enrolment, as well as at 3, 6 and 12 months of ADT. The time-dependent impact of Hb concentration changes on overall survival (OS) was analysed using multivariate Cox proportional hazards analysis. The 10-year OS according to increase/decrease in Hb concentration for the three treatment periods was demonstrated using Kaplan-Meier curves. RESULTS: Multivariate analysis of changes in Hb concentration between baseline and 3 months showed better survival in patients with a decrease in Hb concentration (hazard ratio [HR] 1.42, 95% confidence interval [CI] 1.11-1.80) compared to those with an increase, whilst there was no difference in survival associated with a change in Hb concentration between 3 and 6 months (HR 0.93, 95% CI 0.76-1.12). Contrary to the first 3 months, poorer survival was seen in patients with a decrease in Hb concentration between 6 and 12 months (HR 0.76, 95% CI 0.62-0.92) compared to those with an increase. CONCLUSIONS: In a large cohort of Scandinavian men with hormone-naïve M1b prostate cancer, an increase in Hb concentration between baseline and 3 months of ADT was associated with significantly poorer survival, whereas an increase between 6 and 12 months was associated with better survival. These findings provide new information about patterns of change in Hb concentrations during 12 months of ADT for M1b prostate cancer, and survival. Clinicians should be aware of the prognostic value of Hb concentration changes during ADT in M1b prostate cancer.
引用
- Ebbinge M, Berglund A, Varenhorst E, et al. Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naïve bone-metastatic prostate cancer. BJU Int. 2018. PMID: 29611275. doi:10.1111/bju.14227
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。